ACB
Price
$4.88
Change
-$0.03 (-0.61%)
Updated
Sep 8, 12:30 PM (EDT)
Capitalization
276.04M
59 days until earnings call
CRDL
Price
$1.06
Change
-$0.03 (-2.75%)
Updated
Sep 8, 12:44 PM (EDT)
Capitalization
93.33M
71 days until earnings call
Interact to see
Advertisement

ACB vs CRDL

Header iconACB vs CRDL Comparison
Open Charts ACB vs CRDLBanner chart's image
Aurora Cannabis
Price$4.88
Change-$0.03 (-0.61%)
Volume$1.13K
Capitalization276.04M
Cardiol Therapeutics
Price$1.06
Change-$0.03 (-2.75%)
Volume$200
Capitalization93.33M
ACB vs CRDL Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. CRDL commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and CRDL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ACB: $4.91 vs. CRDL: $1.09)
Brand notoriety: ACB: Notable vs. CRDL: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 57% vs. CRDL: 112%
Market capitalization -- ACB: $276.04M vs. CRDL: $93.33M
ACB [@Pharmaceuticals: Generic] is valued at $276.04M. CRDL’s [@Pharmaceuticals: Generic] market capitalization is $93.33M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileCRDL’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CRDL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACB and CRDL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 7 TA indicator(s) are bullish while CRDL’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 7 bullish, 4 bearish.
  • CRDL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ACB is a better buy in the short-term than CRDL.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -9.41% price change this week, while CRDL (@Pharmaceuticals: Generic) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.10%. For the same industry, the average monthly price growth was +9.00%, and the average quarterly price growth was +87.12%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

CRDL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($276M) has a higher market cap than CRDL($93.3M). ACB YTD gains are higher at: 15.529 vs. CRDL (-14.844). ACB has higher annual earnings (EBITDA): 26.6M vs. CRDL (-39.94M). ACB has more cash in the bank: 140M vs. CRDL (18.2M). CRDL has less debt than ACB: CRDL (143K) vs ACB (102M). ACB has higher revenues than CRDL: ACB (358M) vs CRDL (0).
ACBCRDLACB / CRDL
Capitalization276M93.3M296%
EBITDA26.6M-39.94M-67%
Gain YTD15.529-14.844-105%
P/E Ratio21.12N/A-
Revenue358M0-
Total Cash140M18.2M769%
Total Debt102M143K71,329%
FUNDAMENTALS RATINGS
ACB vs CRDL: Fundamental Ratings
ACB
CRDL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
5564
P/E GROWTH RATING
1..100
82100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (58) in the Pharmaceuticals Other industry is in the same range as CRDL (65) in the null industry. This means that ACB’s stock grew similarly to CRDL’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that ACB’s stock grew similarly to CRDL’s over the last 12 months.

ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that ACB’s stock grew similarly to CRDL’s over the last 12 months.

ACB's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as CRDL (64) in the null industry. This means that ACB’s stock grew similarly to CRDL’s over the last 12 months.

ACB's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that ACB’s stock grew similarly to CRDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCRDL
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
88%
Momentum
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 19 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BNKHF4.66N/A
N/A
BOC Hong Kong (Holdings) Ltd.
JDDSF1.20N/A
N/A
JD Sports Fashion PLC
LJUIF0.43N/A
N/A
SSY GROUP LTD
THNCF1.17-0.13
-9.86%
Thinkific Labs Inc.
PLGGF0.08-0.01
-15.38%
ENERGY PLUG TECHNOLOGIES CORP.

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.66%
CGC - ACB
64%
Loosely correlated
+5.80%
OGI - ACB
63%
Loosely correlated
+2.48%
CRON - ACB
54%
Loosely correlated
N/A
TLRY - ACB
53%
Loosely correlated
+3.48%
PAHC - ACB
31%
Poorly correlated
+0.97%
More

CRDL and

Correlation & Price change

A.I.dvisor tells us that CRDL and ACB have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDL and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDL
1D Price
Change %
CRDL100%
-1.80%
ACB - CRDL
30%
Poorly correlated
+1.66%
EOLS - CRDL
30%
Poorly correlated
+2.00%
LNTH - CRDL
29%
Poorly correlated
+1.73%
SCYX - CRDL
26%
Poorly correlated
+2.43%
TLRY - CRDL
24%
Poorly correlated
+3.48%
More